2024
Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors
Lim S, Lin Y, Lee J, Pedersen B, Stewart A, Scolyer R, Long G, Yang J, Rizos H. Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors. EBioMedicine 2024, 107: 105308. PMID: 39216232, PMCID: PMC11402938, DOI: 10.1016/j.ebiom.2024.105308.Peer-Reviewed Original ResearchMelanoma cellsTranscriptional cell statesTreatment responseSingle-cell RNA sequencingResponse to MAPK inhibitorsPlasticity of melanoma cellsBRAF/MEK inhibitor treatmentImmunotherapy-resistant tumorsMelanoma Institute AustraliaNational Health and Medical Research Council of AustraliaImpact treatment responseMelanoma cell statesPro-inflammatory signalingNational Health and Medical Research CouncilCell statesPro-inflammatory IL6Melanoma tumorsHeterogeneous cancerInhibitor resistanceInhibitor treatmentMelanomaBRAF/MEKRNA sequencingMAPK inhibitorStudy treatment responses
2023
Single cell profiling of tumour biopsies and heterogeneity in response of dedifferentiated melanoma.
Lim E, Lin Y, Pedersen B, Stewart A, Scolyer R, Long G, Yang J, Rizos H. Single cell profiling of tumour biopsies and heterogeneity in response of dedifferentiated melanoma. JCO Global Oncology 2023, 9: 64-64. DOI: 10.1200/go.2023.9.supplement_1.64.Peer-Reviewed Original ResearchResistance to MAPK inhibitionPro-inflammatory IL-6BRAF/MEK inhibitorsIL-6MAPK inhibitionTumor biopsiesAdvanced BRAF V600-mutant melanomaResponse to second-line treatmentTreated with immune checkpoint inhibitorsDT treatmentBRAF-mutant melanoma patientsResponse to MAPK inhibitionMelanoma cellsBRAF V600-mutant melanomaV600-mutant melanomaImmune checkpoint inhibitorsSecond-line treatmentTNFA signalingEx vivo treatmentElevated IL-6Increased IL-6Treated ex vivoDifferentiation stateImmune cell proportionsProportion of melanoma cells